Drug Discovery World

APRIL 18, 2024

For the first time, a controlled human infection model for tuberculosis (TB) has been developed and could help with the future development of TB vaccines. The team states that it’s the first step towards establishing a challenge model that can be used to test new vaccines for TB.

Vaccine 130

Vaccine Clinical Trials Trials Disease 130

Drug Discovery World

OCTOBER 14, 2022

Merck (MSD) and Moderna have revealed plans to work together on the development and commercialisation of an investigational personalised cancer vaccine. With data expected this quarter on PCV, we continue to be excited about the future and the impact mRNA can have as a new treatment paradigm in the management of cancer.”.

Vaccine 244

Vaccine Research Laboratories Laboratories Clinical Development 244

Drug Discovery World

JANUARY 12, 2024

The first clinical trial participants have received doses of the ChAdOx1 NipahB vaccine at the University of Oxford. Despite the first outbreaks occurring 25 years ago in Malaysia and Singapore, there are currently no approved vaccines or treatments.

Virus 130

Virus Vaccine Trials Clinical Trials 130

Drug Discovery World

JANUARY 11, 2024

Researchers have used messenger RNA (mRNA) to create an effective therapy for a rare liver disease in preclinical studies, demonstrating the technology’s potential therapeutic use in people. Patients affected by the disease are found to also experience an imbalance of glutathione regulation, which is important for liver detoxification.

Disease 147

Disease Research RNA Therapies 147

Drug Discovery World

AUGUST 7, 2023

A new Vaccine Development and Evaluation Centre (VDEC) has been unveiled in the UK, with the aim of building on the UK’s pandemic legacy and helping develop life-saving new vaccines that will fight ‘ Disease X ‘, a term used because what might trigger the next pandemic is unknown.

Vaccine 130

Vaccine Virus Clinical Trials Disease 130

Drug Discovery World

SEPTEMBER 18, 2023

Jonathan Riess, lead investigator of the trial at the UC Davis Comprehensive Cancer Center, presented encouraging early clinical and biomarker data supporting the combination treatment for patients with metastatic non-small cell lung cancer (NSCLC). The data show that eight of these 15 patients (53.3%), had a confirmed partial response (PR).

Vaccine 130

Vaccine Trials Therapies Treatment 130

PLOS: DNA Science

OCTOBER 3, 2024

One of the oldest and most successful immunotherapies is simpler: a tamed version of a classic vaccine, against the infectious disease tuberculosis (TB). “BCG” is the “treatment” vaccine’s technical name, for Mycobacterium bovis Bacillus Calmette-Guérin. The approach worked.

52

52

Drug Discovery World

MARCH 30, 2023

Likang Life Sciences has been granted implied approval by China’s National Medical Products Administration (NMPA) for the clinical trial of its innovative personalised neoantigen-targeted vaccine LK101 Injection for advanced solid tumours. Vaccines predicated on neoantigens therefore elicit truly tumour-specific T cell responses.

Vaccine 130

Vaccine Regulations Trials Immune Response 130

Drug Discovery World

JUNE 30, 2023

AC Immune has received Fast Track designation from the US Food and Drug Administration (FDA) for its anti-amyloid beta (Abeta) active immunotherapy (vaccine)-candidate, ACI-24.060, for treatment of Alzheimer’s disease (AD). Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!

FDA 130

FDA Disease Vaccine Treatment 130

Drug Discovery World

OCTOBER 31, 2022

A new study in the US has revealed that the Covid-19 vaccine is less effective in people with weakened immune systems. . The research from the Centers for Disease Control and Prevention’s VISION Network analysed real-world data on mRNA vaccine effectiveness during Omicron BA.4 5 predominance for immunocompromised adults. .

Vaccine 130

Vaccine Virus Hospitals Treatment 130

Drug Discovery World

NOVEMBER 8, 2022

Merck has exercised its option to jointly develop and commercialise personalised cancer vaccine (PCV) mRNA-4157/V940 pursuant to the terms of its existing collaboration and license agreement with Moderna. . The post Merck and Moderna to jointly develop personalised cancer vaccine appeared first on Drug Discovery World (DDW).

Vaccine 130

Vaccine Immune Response Research Laboratories Clinical Trials 130

PPD

JUNE 24, 2024

In the realm of vaccine development, mega trials — studies enrolling 5,000 subjects or more — have been instrumental in the fight against many pathogens, including influenza, rotavirus, malaria, RSV and most recently in the rapid development of vaccines against COVID-19.

Vaccine 97

Vaccine Trials Clinical Trials Laboratories 97

Drug Discovery World

JULY 14, 2022

Pharmaceutical company SIGA Technologies has announced that its oral therapy tecovirimat has been approved in the UK for the treatment of smallpox, monkeypox, cowpox. . The therapy has also been approved for the treatment of complications following vaccination against smallpox in adults and children with a body weight of at least 13kg. .

Treatment 130

Treatment Pharmaceutical Companies Vaccine Virus 130

Drug Discovery World

SEPTEMBER 26, 2024

Immunotherapies are at the cutting edge of therapeutics research, offering some of the most advanced treatments for cancer and other diseases. A new eBook, sponsored by Sino Biological, examines the latest innovations that are driving the market and overcoming the challenges associated with these treatments.

Virus 130

Virus Therapies Vaccine Treatment 130

Drug Discovery World

APRIL 16, 2023

Personalised mRNA-based cancer vaccine mRNA-4157/V940, in combination with the immune checkpoint inhibitor pembrolizumab (Keytruda) improved recurrence-free survival (RFS) compared with pembrolizumab alone in patients with high-risk melanoma. According to the results of the primary trial analysis, after 18 months, the RFS was 78.6%

Vaccine 130

Vaccine Immune Response Medical Schools Trials 130

Drug Target Review

JANUARY 23, 2024

What innovative approaches and technologies are anticipated to reshape immuno-oncology treatments in 2024? Immuno-oncology, notably through checkpoint inhibitors, has significantly reshaped cancer treatment over the past decade.

Treatment 122

Treatment Immune Response Vaccine Therapies 122

Drug Discovery World

JUNE 6, 2024

With the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting , taking place from 30 May to 3 June, the drug discovery announcements have been coming thick and fast, with many new cancer therapies making significant strides forward in our ability to treat the disease.

Drug Research 195

Drug Research Research Vaccine Clinical Trials 195

Drug Discovery World

OCTOBER 24, 2022

A scientist at Oregon State University has demonstrated in a mouse model that it’s possible to prompt the production of a protein that can block multiple variants of the SARS-CoV-2 virus from entering cells and causing respiratory disease. . Once treatment stops, the no-longer-needed soluble hACE2 clears the system in a matter of days.”.

Treatment 100

Treatment RNA Protein Production Virus 100

Drug Discovery World

SEPTEMBER 23, 2024

Insights into this signalling pathway provide a foundation for new approaches to the treatment of cancer and autoimmune diseases as well as vaccine development,” said Daniel Podolsky, President of UT Southwestern. Dr Chen’s discoveries include MAVS, the first mitochondrial protein known to be involved in immunity against infections.

Molecular Biology 147

Molecular Biology Immune Response DNA Virus 147

Drug Discovery World

AUGUST 28, 2024

Therapeutics companies developing immunotherapies, mRNA vaccines and anti-inflammatory therapies have been chosen to receive funding from Innovate UK Biomedical Catalyst. There is currently no cure for leukodystrophies, only symptomatic treatments which aim to maintain physical activity and mobility for as long as possible.

Vaccine 147

Vaccine Drugs Therapies Science 147

Drug Target Review

JANUARY 15, 2024

Cancer is a disease driven by variable genetic mutations. Could you provide insights into the driving factors behind exploring novel treatments for cancer types? Could you provide further details on how this phenomenon could impact broader treatment outcomes? What aspects prompted this research direction?

Treatment 105

Treatment Immune Response Clinical Trials Therapies 105

Drug Discovery World

APRIL 14, 2023

The headlines our attention this week all represent significant breakthroughs in the treatment of various diseases and could make a huge difference to the lives of these patients. There is also new hope for sepsis treatment and for preventing cardiovascular disease in people with HIV thanks to recent research.

Vaccine 130

Vaccine Clinical Trials Drugs Pharmaceutical Companies 130

Drug Discovery World

MAY 3, 2024

Whether it is successful seed funding or dedicated investment, this money enables scientists to produce top-quality research which will in turn result in discoveries and drugs that help tackle disease and areas of unmet need. Cancer vaccine developer secures £12.8m Here are five financial success stories that made headlines this week.

Drugs 130

Drugs Vaccine Disease Treatment 130

Drug Target Review

FEBRUARY 21, 2024

This is a time when several promising treatments – including mRNA vaccines, BiTE therapies and CAR-T cell therapy, are essentially in competition with each other – they all have a common goal of treating the same disease, but they are approaching the objective from different angles.

Therapies 64

Therapies Treatment Vaccine FDA Approval 64

Drug Discovery World

JULY 12, 2024

Despite the revelation from Phesi that a third of clinical trials fail at Phase II, DDW has reported positive human trial updates on therapeutics for myasthenia gravis, non-small cell lung cancer, Marburg virus, and Parkinson’s disease. for disease-modifying Parkinson’s treatment Mission Therapeutics has been awarded $5.2

Clinical Trials 130

Clinical Trials Virus Trials Vaccine 130

FDA Law Blog: Drug Discovery

JUNE 12, 2024

Sasinowski — Hyman, Phelps & McNamara (HPM) would like to congratulate the 7 rare disease programs selected for the inaugural class of the FDA’s “Support for clinical Trials Advancing Rare disease Treatment” (START) pilot program.

Disease 59

Disease Clinical Trials FDA Clinical Development 59

Drug Discovery World

APRIL 19, 2024

The headline news this week all concerns clinical trials for new drugs that could have a significant impact on future patient treatment, including trials testing therapeutics for ALS, cystic fibrosis, gonorrhoea, TB and Parkinson’s. News round-up for 15-19 April by DDW Digital Content Editor Diana Spencer.

Clinical Trials 130

Clinical Trials Vaccine Drugs Trials 130

Drug Discovery World

MARCH 26, 2024

It is approved in adults and adolescents (12 years of age and older weighing at least 40kg) who are moderate-to-severely immune compromised due to certain medical conditions or receipt of certain immunosuppressive medications or treatments and are unlikely to mount an adequate immune response to Covid-19 vaccination.

FDA Approval 130

FDA Approval FDA Clinical Trials Immune Response 130

Drug Discovery World

NOVEMBER 20, 2023

Engineering biology is reshaping the world, from enabling the rapid development of vaccines to providing alternatives to petroleum fuels. mRNA vaccines and antibody therapies in particular are promising areas that are already having significant impact across the healthcare industry, with enormous potential to address unmet medical needs.

DNA 173

DNA Engineering Vaccine Therapies 173

Drug Target Review

SEPTEMBER 7, 2023

host disease risks. The first clinical candidate, BSB-1001, aims to transform leukemia treatment by targeting minor histocompatibility antigen-1. host disease (GVHD) in allogeneic hematopoietic stem cell transplants (alloSCT). leukaemia (GVL) effect while limiting graft-vs-host-disease.

Treatment 98

Treatment Licensing Licensing Disease 98

Drug Discovery World

MAY 23, 2024

A team of scientists in the US and the UK are combining a genetically modified cold sore virus with a cancer vaccine to treat an aggressive type of brain cancer in children. The research team has already used the virus in a small Phase I trial where responses to the treatment were seen in 11 out of 12 children.

Virus 147

Virus Vaccine Immune Response Engineering 147

The Pharma Data

APRIL 26, 2022

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. NYSE: PFE) today reported positive Phase 2 pediatric data for their Lyme disease vaccine candidate, VLA15.

Vaccine 52

Vaccine Disease Protein Expression Trials 52

Drug Discovery World

OCTOBER 27, 2023

My news highlights this week feature a variety of treatment approaches, from cell therapy and antibody-drug conjugate to autotaxin inhibitor and arenaviral vaccine, all entering early in-human clinical trials to treat a range of diseases. News round-up for 23-27 October by DDW Digital Content Editor Diana Spencer.

Vaccine 130

Vaccine Drugs Therapies Clinical Trials 130

Drug Discovery World

JUNE 7, 2023

Compared with traditional mRNA vaccine delivery platforms, the RALA platform has the added advantage of ease of scalability and logistics, including stability at room temperature. pHion’s pipeline also includes differentiated therapeutic vaccines for the treatment of ovarian (PTX_V5) and prostate (PTX_V3) cancers.

Vaccine 130

Vaccine Testimonials Clinical Trials Laboratories 130

Drug Discovery World

AUGUST 12, 2022

New insights into melanoma, a company transition into life sciences and a Lyme disease vaccine are some of the stories in this week’s news round-up. Pfizer launches Phase III trial for Lyme disease vaccine?? . Oxeia Biopharmaceuticals encouraged by concussion treatment? .

Vaccine 130

Vaccine Pharmaceutical Companies Clinical Trials Drugs 130

The Pharma Data

JULY 21, 2021

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, and Pfizer Inc. at Month 7). Juan Carlos Jaramillo M.D., About VLA15.

Vaccine 52

Vaccine Disease Trials Protein Expression 52

PerkinElmer

MAY 28, 2020

Time is of the essence when it comes to the development of a vaccine for the novel infectious disease in our current pandemic. The world has changed due to its impact – and the race to discover a vaccine is crucial for our return to normalcy.

Vaccine 52

Vaccine Disease Virus Small Molecule 52